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RisperidoneThe purpose of this study was to explore the potential of flow imaging microscopy to measure particle
size and agglomeration of poly(lactic-co-glycolic acid) (PLGA) microparticles. The particle size distribu-
tion of pharmaceutical PLGA microparticle products is routinely determined with laser diffraction. In
our study, we performed a unique side-by-side comparison between MFI 5100 (flow imaging micro-
scopy) and Mastersizer 2000 (laser diffraction) for the particle size analysis of two commercial PLGA
microparticle products, i.e., Risperdal Consta and Sandostatin LAR. Both techniques gave similar results
regarding the number and volume percentage of the main particle population (28–220 lm for
Risperdal Consta; 16–124 lm for Sandostatin LAR). MFI additionally detected a ‘fines’ population
(<28 lm for Risperdal Consta; <16 lm for Sandostatin LAR), which was overlooked by Mastersizer.
Moreover, MFI was able to split the main population into ‘monospheres’ and ‘agglomerates’ based on par-
ticle morphology, and count the number of particles in each sub-population. Finally, we presented how
MFI can be applied in process development of risperidone PLGA microparticles and to monitor the phys-
ical stability of Sandostatin LAR. These case studies showed that MFI provides insight into the effect of
different process steps on the number, size and morphology of fines, monospheres and agglomerates
as well as the extent of microparticle agglomeration after reconstitution. This can be particularly impor-
tant for the suspendability, injectability and release kinetics of PLGA microparticles.
 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction that are loaded with risperidone, a small hydrophobic moleculeMicroencapsulation of drugs that are otherwise rapidly
degraded or cleared from the body can prolong the therapeutic
effect from days to several weeks or months [1]. Injectable
microparticles composed of poly(lactic-co-glycolic acid) (PLGA)
polymers are one of the most successful controlled drug delivery
systems, which overcome the need of frequent injections and
thereby improve patient compliance and comfort [2,3]. Better reg-
ulation of the drug release rate also reduces variability in blood
levels, which increases the safety and efficacy of the encapsulated
drug. PLGA microparticles largely owe their success to the biocom-
patibility, biodegradability and adjustable release kinetics of PLGA
polymers.
Two examples of PLGA microparticle products that were suc-
cessfully introduced in the clinic are Risperdal Consta and Sando-
statin LAR [4]. Risperdal Consta consists of PLGA microparticlesthat is used to treat schizophrenia. Adequate therapeutic levels
of risperidone are observed 3 weeks after the first intramuscular
injection, followed by a 2-week period of action [4,5]. Sandostatin
LAR consists of PLGA-glucose microparticles that are loaded with
octreotide acetate, which is the acetate salt of a cyclic octapeptide
that is used to treat acromegaly. Adequate therapeutic levels of
octreotide acetate are observed 2 weeks after the first intramuscu-
lar injection, followed by a 1-month period of action [4,6].
One of the key parameters that governs drug release from PLGA
microparticles is the particle size distribution [7]. For instance, the
particle size of risperidone PLGA microparticles was shown to
affect drug encapsulation efficiency, polymer degradation rate
and initial burst release of the drug [8,9]. In general, smaller PLGA
microparticles have a higher surface-area-to-volume ratio with
more drug molecules on the outer surface that are immediately
accessible and a larger surface available for diffusion, resulting in
increased release rates [10]. The effect will be more pronounced
if the particle porosity is high, since this enhances the particle sur-
face area [11]. Moreover, the presence of larger or agglomerated
particles can affect the suspendability and injectability of a product
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accurately controlled during and after manufacturing. Various pro-
cess parameters are known to affect size and agglomeration of
PLGA microparticles. Some factors that seem crucial for the result-
ing particle size are the volume of organic phase and the method
and duration of agitation during the emulsification step [12,13].
The most common techniques to evaluate PLGA microparticle
size are optical microscopy, scanning electron microscopy (SEM)
and laser diffraction, which have been used since the commercial
launch of the first PLGA microparticle drug delivery systems in
the 1980s. In addition to particle size information, optical micro-
scopy may also provide information on the tendency of PLGA
microparticles to agglomerate [14]. A major drawback of optical
microscopy is that it is time-consuming due to manual sample
preparation (disposing samples onto slides) and low throughput.
Multiple measurements are needed to examine a significant num-
ber of microparticles (typically 100–200) allowing calculation of
the mean diameter. SEM suffers from similar drawbacks with a
laborious sample preparation that may include freeze-drying,
optional cross-sectioning, coating and sample mounting, which
makes this technique mainly suitable for characterizing surface
morphology and internal structure of PLGA microparticles.
By contrast, laser diffraction is less time-consuming owing to a
more straightforward sample preparation and a relatively large
analysis volume at high sample concentration. The technique is
based on a laser beam that is diffracted in a specific pattern
depending on the geometrical dimensions of particles in the sam-
ple. The particle size distribution is derived from the angle and
intensity of the scattered light, which are fitted according to the
Fraunhofer and Mie theories [15]. A limitation of laser diffraction
is that agglomeration of PLGA microparticles cannot be assessed
since samples are not visualized and information on particle mor-
phology is lacking. Thus, the presence of agglomerates may lead to
an overestimation of microparticle size.
In this work, we hypothesized that the relatively new technique
of flow imaging microscopy could combine the advantages of opti-
cal microscopy (visualization of individual particles) and laser
diffraction (high throughput). In recent years, flow imaging micro-
scopy has become increasingly popular for the sizing and counting
of micron-sized particles in therapeutic protein products [16–18].
In particular, Micro-Flow Imaging (MFI) instruments became well
established in the field of subvisible particle analysis [19,20]. In
MFI, microscopic images are automatically collected from a sample
that passes the optics through a flow cell at a rate that is fast
enough to analyze thousands of particles in a few minutes. Particle
size is reported as the equivalent circular diameter (ECD), which is
the diameter of a circle with the same projected area as the parti-
cle. In addition, information on particle count, shape and trans-
parency can be obtained from the analysis software.
The aims of this studywere: (1) to evaluateMFI as a tool to accu-
rately assess the size of PLGA microparticles, and (2) to present an
approach to detect and quantify PLGA microparticle agglomeration
with MFI. For this purpose, we compared MFI with laser diffraction
for Risperdal Consta and Sandostatin LAR, and defined the different
particle populations detected with MFI. Moreover, we showed two
case studies of the application of MFI to support process develop-
ment of risperidone PLGA microparticles and to study the physical
stability of Sandostatin LAR after reconstitution.2. Materials and methods
2.1. Chemicals
Sodium carboxymethyl cellulose (CMC) and poloxamer 188
were purchased from Sigma-Aldrich, D-mannitol from Applichem,polysorbate 80 from Fagron and polyvinyl alcohol (PVA) 4-88 from
Merck. Ultrapure water (18 MX cm) was obtained from a MilliQ
Biocel water purification system (Millipore).
2.2. PLGA microparticles
Risperdal Consta (25-mg vial, Janssen-Cilag B.V., manufactured
by Janssen Pharmaceutica, Beerse, Belgium, batch no. EGS6M/
EBZUECO/EBSK000, exp. 01/2017) and Sandostatin LAR (30-mg
vial, Novartis India, manufactured by Sandoz, Schaftenau, Austria,
lot no. S0016, exp. 02/2016) were purchased locally.
Risperidone-loaded poly(lactic-co-glycolic acid) (PLGA)
microparticles were prepared by using an oil-in-water (O/W)
emulsion solvent extraction method. Samples were taken at differ-
ent stages during the preparation process. The first sample (‘‘emul-
sion”) was collected from the O/W emulsion during the solvent
extraction step, the second sample (‘‘intermediate”) was collected
after concentrating the hardened microparticles over a 25-lm
sieve, and the final sample (‘‘final product”) was collected after
drying. The final, dried product contained a targeted drug load of
38% (w/w) risperidone microencapsulated in 75:25 (lactide:glycol-
ide) PLGA.
To monitor the physical stability of Sandostatin LAR, a 1.0 mg/
ml suspension was prepared in duplicate by dispersing the product
in filtered diluent containing 7.0 g/l CMC, 6.0 g/l D-mannitol and
2.0 g/l poloxamer 188. The sample dispersion was homogenized
and left at room temperature for at least 20 min until the
microparticles visually appeared completely wetted. Next, a 1.0-
ml aliquot was removed for MFI analysis (t = 0 h). The remaining
sample was divided into two portions. One portion was incubated
at 20 C (room temperature) and one portion at 25 C (incubator
type BD240, Binder) in glass vials (20-ml liquid scintillation vials,
Sigma-Aldrich). After 4, 24 and 52 h of incubation, 1.0-ml aliquots
were removed for MFI analysis.
2.3. Particle size distribution with Mastersizer
Particle size distributions of Risperdal Consta and Sandostatin
LAR were measured by using a Malvern Mastersizer 2000 laser
diffraction instrument equipped with a Micro Precision Hydro
2000lP sample dispersion unit (Malvern Instruments). Three mea-
surements were performed per sample and two samples were
taken per product. The dispersion unit was drained and flushed
with ultrapure water between sample measurements and back-
ground detector intensities were checked to ensure cleanliness of
the sample compartment.
2.3.1. Mastersizer measurement of Risperdal Consta
Risperdal Consta vials were equilibrated at room temperature
for at least 30 min prior to reconstitution. Microparticles (10 mg/
ml) were dispersed in 0.01% (w/v) polysorbate 80 and sonicated
for 1–2 min. The sample dispersions were measured within
30 min upon preparation and homogenized just before measure-
ment. A sample volume of approximately 2 ml was added into
the 20-ml dispersion unit prefilled with ultrapure water and more
sample was added until an obscuration level between 5 and 10%
was reached. Stirring rate in the dispersion unit was set at
1500 rpm without ultrasonication. The detector array measured
the scattering pattern during 20 s.
2.3.2. Mastersizer measurement of Sandostatin LAR
Sandostatin LAR microparticles (24 mg/ml) were dispersed in
0.3% (w/v) polysorbate 80, homogenized and left at room temper-
ature for at least 15 min. The sample dispersions were homoge-
nized again just before measurement. A sample volume of
approximately 1 ml was added into the 20-ml dispersion unit
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the obscuration level reached a value between 4 and 6%. Stirring
rate in the dispersion unit was set at 1200 rpm without ultrasoni-
cation. The detector array measured the scattering pattern during
30 s.
2.3.3. Mastersizer data analysis
The Mastersizer raw data were analyzed with the Malvern
Mastersizer 2000 software (version 5.22) using the Fraunhofer
model (ndispersant = 1.330), general purpose mode, normal calcula-
tion sensitivity and assuming an irregular particle shape. Number
and volume % results were exported for particle sizes ranging from
2 to 222 lm with a bin size of 4 lm. Number and volume per-
centiles, spans, surface mean d[3,2] and volume mean d[4,3] were
obtained from the software. Volume-based particle size distribu-
tions were fitted with a medium Lowess curve (with a smoothing
window of 10 points) in GraphPad Prism 5 (version 5.02) to deter-
mine the volume mode.
2.4. Particle size distribution with Micro-Flow Imaging (MFI)
MFI measurements were performed with an MFI 5100 instru-
ment (featuring a flow cell depth of 400 lm) equipped with a
high-throughput BOT1 autosampler (ProteinSimple). Data were
acquired with MFI View System Software (MVSS) version 2-R4
and processed with MFI View Analysis Suite (MVAS) software ver-
sion 1.4.0. Sample diluents were filtered through a Millex-GP 0.22-
lm sterile syringe filter (Millipore). A baseline measurement was
performed with sample diluent to ensure that less than 500 parti-
cles/ml were present. Optimize illumination was performed on the
sample diluent and samples were stirred 12 times at a speed of 6
before they were introduced into the sample port. The sample
purge volume was set at 0.20 ml and the analyzed sample volume
was 0.571 ml. At least 3000 particles were analyzed per measure-
ment and samples were measured in triplicate. The reported parti-
cle size (in lm) is the equivalent circular diameter (ECD) detected
by MFI.
2.4.1. MFI sample preparation
Risperdal Consta (1.0 mg/ml) and the final, dried product of
risperidone PLGA microparticles (1.0 mg/ml) were dispersed in fil-
tered diluent containing 0.5% (w/v) polysorbate 80. Sandostatin
LAR (0.5 mg/ml) was dispersed in filtered diluent containing
7.0 g/l CMC, 6.0 g/l D-mannitol and 2.0 g/l poloxamer 188. The sam-
ple dispersions were homogenized and left at room temperature
for at least 20 min until the microparticles visually appeared com-Fig. 1. MVAS filter manager settings for Risperdal Consta and Sandostatin LAR devel
agglomerates. For in-house produced risperidone PLGA microparticles, the Risperdal Copletely wetted. Emulsion and intermediate samples of risperidone
PLGA microparticles were diluted in 5% (w/v) PVA 4–88 until less
than 13,000 particles were analyzed per measurement. The
samples were homogenized just before transferring 1.0 ml to a
96-well plate (Eppendorf) suitable for the Bot1 autosampler.
2.4.2. MFI data analysis
Edge particles were removed from MFI raw data with the MVAS
software. Number and volume % results were exported for particle
sizes ranging from 2 to 222 lm with a bin size of 4 lm. Number
percentiles were obtained from the software. Volume percentiles
were determined from the cumulative size distribution curve,
where Dv10, Dv50 and Dv90 percentiles are the diameters at 10%,
50%, and 90% cumulative particle volume, respectively. The width
of the number- and volume-based size distributions was calculated
as the span according to Eqs. (1) and (2):
Number span ¼ ðDn90 Dn10ÞðDn50Þ ð1Þ
Volume span ¼ ðDv90 Dv10ÞðDv50Þ ð2Þ
The surface mean d[3,2] and volume mean d[4,3] were calcu-












where: Di = ECD of the ith particle.
Volume-based size distributions were fitted by using GraphPad
Prism with a medium Lowess curve (10-points smoothing win-
dow) to determine the volume mode. The cumulative particle vol-
ume and surface were calculated and divided by the number of
measured particles to obtain the mean particle volume and surface.
2.4.3. Particle classification
By using the filter manager in the MVAS software, ECD and
aspect ratio cutoffs were set to distinguish three different particle
populations: ‘‘fines”, ‘‘monospheres” and ‘‘agglomerates”. A cus-
tomized filter was defined for each PLGA microparticle product
(Fig. 1). For Risperdal Consta and intermediate and final product
samples of risperidone PLGA microparticles, filter cutoffs wereoped to classify particles according to three categories: fines, monospheres and
nsta filter settings were used.
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LAR, filter cutoffs were set at an ECD of 16 lm and an aspect ratio
of 0.89. Application of the customized filters, as shown in Fig. 1,
was followed by visual examination of particle images of the
monospheres population to identify and select any additional
agglomerates that were misclassified as monospheres. Manual
selection of agglomerated particles within the monospheres popu-
lation resulted in 0.1–2.7 vol% of additional agglomerates.
3. Results and discussion
3.1. Particle size distributions obtained with MFI versus Mastersizer
Two commercial PLGA microparticle products, Risperdal Consta
and Sandostatin LAR, were characterized by using the established
Mastersizer technique and the relatively novel technique of MFI
(Fig. 2). While MFI detects individual particles and thus providesFig. 2. Particle size distributions of (A, B) Risperdal Consta and (C, D) Sandostatin LAR m
For each particle size, the corresponding (A, C) number and (B, D) volume percentages are
(±standard deviation). MFI results are the mean of three samples (+standard deviation
referred to the web version of this article.)primarily number-based results, these can be converted to
volume-based results by assuming spherically shaped particles.
The Mastersizer instrument uses the volume of particles to deter-
mine their diameter, but the fundamental volume distribution can
be transformed to number distribution, also by assuming spherical
particles, with the Mastersizer 2000 software. In order to compare
MFI with Mastersizer results, particle size distributions are
presented in number % (Fig. 2A and C) as well as volume %
(Fig. 2B and D).
Number and volume size distributions measured with Master-
sizer and MFI were substantially similar for the main particle frac-
tion of Risperdal Consta (between 28 lm and 220 lm) and
Sandostastin LAR (between 16 lm and 124 lm). However, an addi-
tional fraction of smaller particles (<28 lm for Risperdal Consta
and <16 lm for Sandostatin LAR) was clearly visible with MFI,
but not with Mastersizer, in the number-based size distribution
(Fig. 2A and C). Also, modelling the Mastersizer raw data accordingeasured with Mastersizer (red curve) and Micro-Flow Imaging (MFI, grey size bins).
shown. Mastersizer results are the mean of two samples each measured in triplicate
). (For interpretation of the references to color in this figure legend, the reader is
Table 1
Particle size distribution characteristics of Risperdal Consta and Sandostatin LAR measured with Mastersizer and Micro-Flow Imaging (MFI). Number and volume percentiles and
span values are shown, as well as other relevant particle size distribution characteristics that can be calculated fromMastersizer and/or MFI data. Mastersizer results are the mean
of two samples each measured in triplicate (±standard deviation). MFI results are the mean of three samples (±standard deviation).
Risperdal Consta Sandostatin LAR
Mastersizer MFI Mastersizer MFI
Number percentiles
Dn10 (lm) 39.3 ± 0.9 3.6 ± 0.4 30.9 ± 1.0 2.1 ± 0.0
Dn50 (lm) 57.9 ± 0.9 47.4 ± 0.8 42.3 ± 1.1 35.7 ± 0.5
Dn90 (lm) 94.4 ± 0.8 92.5 ± 2.5 61.3 ± 0.3 56.2 ± 0.2
Number span 0.95 ± 0.02 1.88 ± 0.02 0.72 ± 0.04 1.52 ± 0.02
Volume percentiles
Dv10 (lm) 54.0 ± 0.6 51.3 ± 1.1 37.5 ± 0.8 38.4 ± 0.7
Dv50 (lm) 89.1 ± 0.3 92.3 ± 2.9 54.3 ± 0.1 53.5 ± 0.4
Dv90 (lm) 143.0 ± 0.0 129.5 ± 3.4 79.0 ± 2.0 80.7 ± 2.7
Volume span 1.00 ± 0.01 0.85 ± 0.02 0.77 ± 0.05 0.79 ± 0.04
Other characteristics
Surface mean d[3,2] (lm) 82.5 ± 0.5 81.1 ± 2.6 52.1 ± 0.1 52.6 ± 0.7
Volume mean d[4,3] (lm) 94.4 ± 0.3 92.3 ± 3.8 56.6 ± 0.4 57.2 ± 0.7
Volume mode (lm) 76.0 ± 0.0 101.3 ± 5.9 48.4 ± 0.0 48.4 ± 0.0
Cumulative surface (mm2) Not available with Mastersizer 47.0 ± 4.6 Not available with Mastersizer 13.5 ± 0.9
Cumulative volume (ll) 0.64 ± 0.08 0.12 ± 0.01
Particle concentration (#/ml) 7505 ± 379 5359 ± 169
Total number of particles 4286 ± 216 3061 ± 97
Mean particle surface (mm2) 0.011 ± 0.001 0.004 ± 0.000
Mean particle volume (nl) 0.148 ± 0.012 0.039 ± 0.002
Fig. 3. Scatter plots with the aspect ratio and equivalent circular diameter (ECD) of
particles in individual samples of (A) Risperdal Consta and (B) Sandostatin LAR
measured with Micro-Flow Imaging (MFI).
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‘‘multiple narrow modes” instead of the ‘‘general purpose mode”
did not allow detection of the smaller particles in presence of the
main PLGA microparticle fraction (data not shown).
This discrepancy between Mastersizer and MFI was reflected in
the number percentiles and number span values calculated for
both products, while volume percentiles and volume span values
corresponded well between the two techniques (Table 1). In partic-
ular, the Dn10 values measured with MFI were much smaller than
those measured with Mastersizer (3.6 ± 0.4 lm vs. 39.3 ± 0.9 lm
for Risperdal Consta; 2.1 ± 0.0 lm vs. 30.9 ± 1.0 lm for Sandostatin
LAR), because Mastersizer did not detect the smaller particle frac-
tion. Accordingly, number span values reported by MFI were signif-
icantly larger than those reported by Mastersizer (1.88 ± 0.02 vs.
0.95 ± 0.02 for Risperdal Consta; 1.52 ± 0.02 vs. 0.72 ± 0.04 for San-
dostatin LAR), due to the wider number size distribution detected
with MFI.
A similar observation was done by Farrell et al. [21], who ana-
lyzed cell culture microcarriers with Mastersizer and MFI. The
researchers showed that MFI was able to detect smaller particles
(<50 lm) that were overlooked by Mastersizer in presence of lar-
ger particles (with an average ECD of 176 lm), and explained this
by the difference in measurement principle (i.e., number-based
versus volume-based). Smaller particles are probably missed by
the Mastersizer because the light scattering signal, which relates
to volume % rather than number %, is dominated by the larger par-
ticles. In addition, Mastersizer measures all particles simultane-
ously and gives an approximate representation of the volume
distribution, whereas MFI measures individual particles [21]. This
also explains why our Mastersizer results appear as smooth aver-
aged curves, while MFI results are much more affected by the pres-
ence of individual particles (Fig. 2).
The particle sizes of Risperdal Consta reported in the literature
lay between 25 and 150 lm [22], with an approximate average size
of 0.1 mm [23], and the reported average size of Sandostatin LAR
detected by scanning electron microscopy is about 50 lm [24].
The volume means d[4,3] of Risperdal Consta and Sandostatin
LAR that we measured with MFI (92.3 ± 3.8 lm and
57.2 ± 0.7 lm, respectively) closely match those measured with
Fig. 4. Exemplary images of particles in Risperdal Consta and Sandostatin LAR captured with Micro-Flow Imaging (MFI). Particles are divided into three different categories,
i.e., fines, monospheres and agglomerates, based on their equivalent circular diameter (ECD) and aspect ratio provided by the MFI View Analysis Suite (MVAS) software.
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(Table 1), and also agree with literature values. Importantly, MFI
provides additional number-based information that is not avail-
able with Mastersizer such as particle concentration, mean particle
surface and mean particle volume (Table 1). Moreover, MFI shows
higher sensitivity towards sample-to-sample or batch-to-batch
variations owing to its ability to measure individual particles and
provide information about their morphology (see Section 3.2).
These major advantages can be of great importance for the purpose
of pharmaceutical development and quality control of PLGA
microparticle products.1 For interpretation of color in Figs. 3 and 9, the reader is referred to the web
version of this article.3.2. Particle classification with MFI in Risperdal Consta and
Sandostatin LAR
MFI, as an imaging technique, not only provides the ECD of indi-
vidual particles, but also gives information on particle morphology.
One of those morphological parameters is the aspect ratio, defined
as ‘‘the ratio of the minor axis length over the major axis length of
an ellipse that has the same second-moments as the particle” with
values ranging from 0 to 1 (no units; 1 for a perfect circle) [25].
Based on a scatter plot of aspect ratio as a function of ECD, three
distinct particle populations could be distinguished in Risperdal
Consta and Sandostatin LAR (Fig. 3).
The population defined as ‘‘fines” consisted of the smaller par-
ticle fraction (<28 lm for Risperdal Consta and <16 lm for Sando-
statin LAR) and displayed a wide range of aspect ratios from 0.28 to
1, which suggests that the shape of these particles varied from rod-
like or fibrous to perfectly spherical. Particle images corresponding
to the fines captured by MFI indeed showed a wide variety ofshapes (Fig. 4). A clear size gap was present in the scatter plots
of both products between the fines and two other populations,
i.e., ‘‘monospheres” and ‘‘agglomerates”. Monospheres appeared
to be close to spherical with aspect ratios >0.85 for Risperdal Con-
sta and 0.89 for Sandostatin LAR, whereas agglomerates con-
sisted of multiple spheres resulting in lower aspect ratios (Figs. 3
and 4).
A filter was developed in MVAS based on the mentioned ECD
and aspect ratio cutoffs (Fig. 1). To verify the ability of the filter
to distinguish agglomerates from monospheres, the images of
particles defined as monospheres were visually examined. In gen-
eral, this resulted in the identification of a few volume percent of
additional agglomerates with high aspect ratios (>0.85), such as
the agglomerates (red1 open squares) that can be seen within the
monospheres population (blue open circles) in Risperdal Consta
(Fig. 3A). Based on the MVAS filters combined with visual examina-
tion, separate number and volume size distributions could be gener-
ated for the fines, monospheres and agglomerates in Risperdal
Consta and Sandostatin LAR (Fig. 5). Also, the number %, volume %,
Dv50, volume span and volume mode were calculated for each par-
ticle population (Table 2).
Although the fines contributed considerably to the total number
of particles (16.5 ± 0.9% and 37.2 ± 0.4%, respectively for Risperdal
Consta and Sandostatin LAR), their contribution to the total particle
volume was negligible (<0.05% for both products). The nature of
these fines could be extrinsic (contaminants), intrinsic (related to
the drug product) or inherent (originating from the drug product)
Fig. 5. Particle size distributions of the different populations (i.e., fines, monospheres and agglomerates) in (A, B) Risperdal Consta and (C, D) Sandostatin LAR measured with
Micro-Flow Imaging. Size distributions are shown as (A, C) number and (B, D) volume percentages. Results are the mean of three samples (+standard deviation).
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sic particles, such as dust or hair fragments, that contaminated the
sample during sample preparation or MFI measurement. As a con-
trol, baseline measurements were performed with sample diluent,
which generally showed particle concentrations that were 5–10
times lower than the fines population in commercial PLGA
microparticle samples (data not shown). Thus, most likely mainly
intrinsic and/or inherent particles were present in the fines popu-
lation. In the case of cell culture microcarriers, researchers sug-
gested that the main particle fraction was accompanied by a
smaller particle fraction originating from debris produced during
manufacturing of the microcarriers [21]. In the case of PLGA
microparticles, debris in the form of fine PLGA particles or frag-
ments may have been formed during the Risperdal Consta and San-
dostatin LAR manufacturing processes.
The main particle population produced during manufacturing
consisted of monospheres with a Dv50 of 85.1 ± 1.1 lm for Ris-
perdal Consta and 48.5 ± 0.5 lm for Sandostatin LAR (Table 2).Risperdal Consta monospheres showed slightly lower aspect ratios
and broader size distributions (span value 0.83 ± 0.03) than
Sandostatin LAR monospheres (span value 0.48 ± 0.02). Besides
fines and monospheres, a considerable volume fraction of agglom-
erated PLGA microparticles was present in Risperdal Consta
(25.1 ± 3.8%) and Sandostatin LAR (31.4 ± 1.7%). These agglomer-
ates may have been formed during manufacturing and/or storage
of the products. Moreover, Risperdal Consta agglomerates gener-
ally consisted of two or three PLGA microparticles that were
slightly misshaped, whereas Sandostatin LAR agglomerates con-
sisted of two, three or multiple PLGA microparticles that were
nearly spherical (Fig. 4). These differences in particle characteris-
tics may be the result of the different encapsulation techniques
associated with the two commercial products, i.e., O/W emulsion
solvent extraction for Risperdal Consta and coacervation for
Sandostatin LAR [26]. Also, PLGA properties (such as PLGA versus
PLGA-glucose star polymer, co-monomer ratio, molecular weight),
drug properties of risperidone (a small hydrophobic molecule)
Fig. 6. Scatter plots with the aspect ratio and equivalent circular diameter (ECD) of
particles in the (A) emulsion, (B) intermediate, and (C) final product of risperidone
PLGA microparticles measured with Micro-Flow Imaging.
Table 2
Particle size distribution characteristics of the different populations (i.e., fines,
monospheres and agglomerates) in Risperdal Consta and Sandostatin LAR measured
with Micro-Flow Imaging. The number percentage, volume percentage, median
particle size (Dv50), volume span, and volume mode of each population are shown.
Results are the mean of three samples (±standard deviation).
Risperdal Consta Sandostatin LAR
Fines Number % 16.5 ± 0.9 37.2 ± 0.4
Volume % <0.05 <0.05
Dv50 (lm) 20.0 ± 2.0 8.0 ± 0.4
Volume span 1.01 ± 0.12 1.39 ± 0.04
Volume mode (lm) 18.5 ± 2.3 12.7 ± 0.5
Monospheres Number % 75.4 ± 0.8 55.9 ± 0.3
Volume % 74.9 ± 3.9 68.5 ± 1.6
Dv50 (lm) 85.1 ± 1.1 48.5 ± 0.5
Volume span 0.83 ± 0.03 0.48 ± 0.02
Volume mode (lm) 90.8 ± 7.8 46.4 ± 1.7
Agglomerates Number % 8.2 ± 0.9 6.9 ± 0.5
Volume % 25.1 ± 3.8 31.4 ± 1.7
Dv50 (lm) 114.3 ± 5.2 74.1 ± 1.7
Volume span 0.66 ± 0.08 0.51 ± 0.03
Volume mode (lm) 112.2 ± 4.0 70.7 ± 2.3
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mulation of the product and storage conditions can have an effect
on the size distribution and agglomeration behavior of the
microparticles.
In general, formulation and process parameters as well as stor-
age conditions can have a large impact on the size characteristics of
PLGA microparticles, affecting the drug release profile and thus the
efficacy and safety in patients. Our results show that MFI is an
excellent tool for in-depth PLGA microparticle characterization.
Not only the size distribution and morphology of the main particle
population (monospheres) can be assessed, but MFI also enables us
to distinguish and quantify other populations such as fines and
agglomerates.
3.3. Case study 1: process development of risperidone PLGA
microparticles
Here, we present an example of applying MFI as a tool to mon-
itor particle size and agglomeration during the manufacturing pro-
cess of a PLGA microparticle product. One batch of risperidone
loaded PLGA microparticles was prepared in-house by using an
O/W emulsion solvent extraction method. Formulation and process
parameters were chosen to obtain a final product with similar
properties as Risperdal Consta (38% (w/w) drug loading, 75:25 (lac-
tide:glycolide) PLGA, and similar particle size distribution). To
study the effect of certain process steps on particle characteristics,
samples were taken at three different stages during the prepara-
tion of risperidone PLGAmicroparticles and measured off-line with
MFI.
The first sample (‘‘emulsion”) was collected during the solvent
extraction step after emulsification. During emulsification, the
organic phase containing risperidone and PLGA was mixed with
an aqueous, continuous phase in presence of a stabilizing agent
to form emulsion droplets. Subsequently, the O/W emulsion was
added to a large volume of aqueous phase to remove solvent from
the emulsion droplets (solvent extraction). The size distribution of
the emulsion droplets, which are the precursors of microparticles,
may depend on stabilizer concentration, viscosity, mixing time,
and amount of shear applied during emulsification [7,12,27,28].
For example, the speed of stirring during emulsification was shown
to affect particle size and the extent of agglomeration in the final,
lyophilized PLGA microparticle product [29]. Thus, process
parameters during the emulsification phase will provide a basis
for the size distribution of the final product.Interestingly, the emulsion droplets in our sample did not show
distinct particle populations according to the scatter plot (Fig. 6A).
There was no size gap present at lower ECD values in the particle
size distribution (Fig. 7A and B), indicating that a distinct fines pop-
ulation was not present yet at this stage of the manufacturing pro-
cess. Moreover, emulsion droplets in the full ECD range appeared
as individual spheres and examination of MFI images did not reveal
any agglomerates. An explanation for the absence of agglomerates
may be that if one emulsion droplet encounters another droplet,
Fig. 7. Particle size distributions of the different populations (i.e. fines, monospheres and agglomerates) in the (A, B) emulsion, (C, D) intermediate, and (E, F) final product of
risperidone PLGA microparticles measured with Micro-Flow Imaging. Size distributions are shown as (A, C, E) number and (B, D, F) volume percentages. Results are the mean
of three samples (+standard deviation).
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sample consisted of monospheres only with a Dv50 of
86.5 ± 3.7 lm and a relatively wide volume span of 1.58 ± 0.53
(Table 3).The second sample (‘‘intermediate”) contained wet microparti-
cles collected on a 25-lm sieve after the solvent extraction step
(Fig. 6B). Solvent removal caused the emulsion droplets to solidify
and form hardened microparticles. Particle size and morphology
Table 3
Particle size distribution characteristics of the different populations (i.e. fines, monospheres and agglomerates) in the emulsion, intermediate, and final product of risperidone
PLGA microparticles measured with Micro-Flow Imaging. The number percentage, volume percentage, median particle size (Dv50), volume span and volume mode of each
population are shown. Results are the mean of three samples (±standard deviation).
Emulsion Intermediate Final product
Total Dv50 (lm) 86.5 ± 3.7 89.3 ± 1.4 112.3 ± 1.7
Volume span 1.58 ± 0.53 1.16 ± 0.26 1.47 ± 0.07
Volume mode (lm) 87.8 ± 3.9 88.2 ± 0.6 86.8 ± 6.5
Fines Number % No fines detected 11.1 ± 0.7 50.6 ± 21.0
Volume % <0.05 0.1 ± 0.1
Dv50 (lm) 23.9 ± 1.3 20.0 ± 2.8
Volume span 0.73 ± 0.04 0.91 ± 0.22
Volume mode (lm) 23.7 ± 0.0 17.5 ± 2.1
Monospheres Number % 100.0 ± 0.0 86.5 ± 0.6 43.8 ± 18.6
Volume % 100.0 ± 0.0 87.9 ± 0.1 43.8 ± 1.2
Dv50 (lm) 86.5 ± 3.7 86.1 ± 0.9 78.3 ± 1.2
Volume span 1.58 ± 0.53 0.99 ± 0.15 0.81 ± 0.03
Volume mode (lm) 87.8 ± 3.9 88.2 ± 0.6 82.6 ± 4.6
Agglomerates Number % No agglomerates detected 2.4 ± 0.3 5.6 ± 2.4
Volume % 12.1 ± 0.2 56.1 ± 1.2
Dv50 (lm) 133.2 ± 19.2 155.6 ± 2.0
Volume span 0.91 ± 0.05 0.87 ± 0.07
Volume mode (lm) 141.4 ± 12.7 140.1 ± 7.9
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trolled by the aqueous phase composition, co-solvent concentra-
tion, solid-to-liquid ratio, temperature, and stirring speed [30,31].
The scatter plot of our intermediate sample revealed the presence
of the same three types of particle populations as described in the
previous section, i.e., fines, monospheres and agglomerates
(Fig. 6B).
The corresponding number size distribution indicated that the
total number percentage of particles smaller than 28 lm in the
intermediate sample was much lower than in the emulsion sample,
and the intermediate sample also showed a clear size gap between
the fines and monospheres population (Fig. 7C). This is probably
because the sieving step removed many particles smaller than
25 lm, but not all of them. The efficiency of sieving may not be
100% due to adherence of small particles to the surface of larger
particles that are unable to travel through the sieve. This type of
sieving might also explain the presence of the fines population in
the two commercial products, Risperdal Consta and Sandostatin
LAR.
Importantly, the solvent extraction and wet sieving step did not
seem to affect the Dv50 of the monospheres (emulsion
86.5 ± 3.7 lm; intermediate 86.1 ± 0.9 lm), but it caused the for-
mation of 12.1 ± 0.2 vol% of agglomerates with a Dv50 of
133.2 ± 19.2 lm (Table 3). There may be several reasons for
agglomeration at this stage. One possible reason may be that the
microparticles were not fully solidified due to a relatively high
residual solvent content, resulting in a higher tendency to agglom-
erate in the concentrating and sieving process [7,13,31,32]. Also, a
stabilizer concentration that is too high may result in an increased
number of agglomerated microparticles during solidification [26].
Lastly, a sample of the final, dried product was measured with
MFI (Fig. 6C). Again, the three particle populations could clearly
be detected (Fig. 7E). Although the fines did not significantly con-
tribute to the volume distribution (Fig. 7F), the number percentage
of fines was enhanced in the final product (50.6 ± 21.0%) compared
with the intermediate sample (11.1 ± 0.7%) (Table 3). A reason for
this may be that additional fines could have been released from
larger particles during the final drying step, which included shear
forces.
Furthermore, an increase in the Dv50 of the total particle popu-
lation was observed compared with the intermediate sample
(intermediate 89.3 ± 1.4 lm; final product 112.3 ± 1.7 lm)
(Table 3). The increase in the Dv50 of the total particle population
could not be explained by a growth in the size of themicroparticles, but was due to a remarkable increase in volume
percentage of agglomerates (intermediate 12.1 ± 0.2%; final
product 56.1 ± 1.2%). The Dv50 of the monospheres population
even decreased (intermediate 86.1 ± 0.9 lm; final product
78.3 ± 1.2 lm), likely due to shrinkage of the particles upon drying.
It is clear that, in our case study, the final drying step was primarily
responsible for the high degree of agglomeration. With this knowl-
edge one may be able to adjust the process parameters in order to
prevent agglomeration. For instance, the use of an aqueous solu-
tion of mannitol was reported to prevent agglomeration upon
freeze-drying of risperidone PLGA microparticles [8].
In summary, MFI provides detailed insight into the impact of
successive process steps on PLGA microparticle characteristics.
More specific, microparticle size and the formation of different par-
ticle populations can be followed during the preparation process.
Information obtained with this technique provides a basis for find-
ing the right process parameters to achieve an optimal particle size
distribution that gives the desired suspendability, injectability and
release kinetics.
In this case study we have shown results from off-line MFI anal-
yses, but in future applications it may even be possible to deploy
MFI for on-line measurements. Following a quality-by-design
approach, one could imagine employing MFI as process analytical
technology tool during PLGA microparticle manufacturing [33],
e.g., to decide when to stop the emulsification process (at steady
state or at the desired droplet size). Moreover, it seems to be a
suitable and relatively straightforward method for the purpose of
quality control.
3.4. Case study 2: monitoring the physical stability of Sandostatin LAR
In addition to manufacturing process parameters, it is impor-
tant to assess the impact of transport, storage and handling on
the (particle) characteristics of PLGA microparticle products, since
these may significantly impact product quality. For this reason, the
physical stability of PLGA microparticle products should be evalu-
ated before and after reconstitution.
Sandostatin LAR dry powder is relatively stable for a prolonged
period of time at 2–8 C, or for at least 1 h at room temperature [6].
However, after mixing the Sandostatin LAR dry powder with the
diluent, the drug suspension must be administered immediately
(within 2–3 min) because of the high tendency of the microparti-
cles to agglomerate after reconstitution [6,34]. In case of micropar-
ticle agglomeration, it becomes difficult or even impossible to
Fig. 8. Volume-based particle size distributions of Sandostatin LAR measured with Micro-Flow Imaging during incubation at 25 C. Samples were analyzed after
reconstitution at (A) 0 h, and after incubation of the reconstituted product for (B) 4 h, (C) 24 h, and (D) 52 h at 25 C. Results are the mean of two samples (+standard
deviation). Incubation of reconstituted Sandostatin LAR at 20 C for 4, 24 and 52 h did not result in a significant change in the size distribution (data not shown).
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loss. This is in sharp contrast with Risperdal Consta, which can
be kept at 25 C for up to 6 h after reconstitution without
injectability issues [35]. In this case study, we evaluated the phys-
ical stability of Sandostatin LAR after reconstitution, by monitoring
particle size and agglomeration in time with MFI.
Directly after reconstitution and complete suspension of the
drug product, a first baseline MFI measurement (0 h) was per-
formed (Fig. 8A). The volume-based particle size distributions of
fines, monospheres and agglomerates corresponded well with
those previously measured in Sandostatin LAR (Fig. 5D). After 4 h
of incubation at 25 C, several larger agglomerates (>124 lm) were
formed and the volume percentage of agglomerates in the com-
plete size range appeared to increase, while the volume percentage
of monospheres decreased (Fig. 8B). A further increase in volume
percentage of agglomerates and a concomitant decrease in volume
percentage of monospheres were apparent at 24 and 52 h(Fig. 8C and D). In contrast, no significant changes were observed
over time in the size distributions of the fines, monospheres and
agglomerates during incubation of reconstituted Sandostatin LAR
at 20 C for up to 52 h (data not shown).
Importantly, incubation at 25 C resulted in a significant
decrease in the total particle concentration, expressed as number
of particles per ml (Fig. 9A, black line, closed triangles). This was
caused by a decrease in the number of monospheres (Fig. 9A, blue
line, closed circles), which logically was relatively large compared
with the smaller increase in the number of agglomerates (Fig. 9A,
red line, closed squares). This implies that two or more mono-
spheres attached to each other to form one agglomerate. Ongoing
agglomeration also resulted in a significantly larger volume span
of the agglomerates at 52 h than at 0 h, pointing to widening of
the size distribution for this population (Fig. 9B).
The median particle size (Dv50) of the total particle population
shifted to larger sizes in the course of time, which was not due to
Fig. 9. Stability of Sandostatin LAR monitored with Micro-Flow Imaging and measured at 0, 4, 24 and 52 h after reconstitution. The (A) particle concentration, (B) volume
span, and (C) median particle size of the different particle populations (i.e. total, fines, monospheres and agglomerates) in reconstituted Sandostatin LAR incubated at 25 C
are presented. Moreover, the (D) volume percentages of monospheres and agglomerates are shown during incubation at 20 C (dashed lines) and 25 C (solid lines). Results
are the mean of two samples (±standard deviation). Unpaired, two tailed t tests were performed to compare the results at 0 and 52 h (* p < 0.05, ** p < 0.01, *** p < 0.001).
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(Fig. 9C). However, the Dv50 shift of the total particle population
could be explained by a substantial increase in the volume per-
centage of agglomerates (from 37.5 ± 2.3% at 0 h to 73.9 ± 1.0% at
52 h), together with an equivalent decrease in the volume percent-
age of monospheres (from 62.4 ± 2.3% at 0 h to 26.1 ± 1.0% at 52 h)
(Fig. 9D). Remarkably, there was no significant increase or decrease
in the volume percentage of any of the populations for reconsti-
tuted Sandostatin LAR incubated at 20 C for 52 h (Fig. 9D).
The substantial agglomeration propensity of reconstituted San-
dostatin LAR at 25 C may be related to the use of PLGA-glucose
star polymer instead of the normal PLGA polymer. In PLGA-
glucose star polymer, the free acid end groups of PLGA are reacted
with the hydroxyl groups of a core glucose unit, forming a star-
shaped structure. PLGA-glucose has several advantages over con-
ventional PLGA for encapsulating proteins and peptides (such as
octreotide) [36]. Most importantly, it limits the initial burst release
that poses a serious threat in terms of toxicity. It also features
longer polymer degradation times and reduced risk of acylation
of the encapsulated protein or peptide, owing to the absence of free
acid end groups.
Another characteristic of PLGA-glucose microparticles is that
hydration is enhanced due to the presence of the hydrophilic glu-cose core [37–39]. The Tg of PLGA-based products is known to
decrease tremendously upon hydration following reconstitution
[40,41]. Kang et al. [39] concluded that the polymer chains at the
surface of PLGA-glucose microparticles rapidly became more flex-
ible within 2 h of hydration and formed a nonporous film on the
previously porous surface. We suggest that in our case study the
Tg of the PLGA-glucose polymers on the surface of reconstituted
Sandostatin LAR decreased to a temperature close to 25 C within
4 h of reconstitution. Incubation at 25 C, but not at 20 C, may
have modified the surface of the reconstituted PLGA-glucose
microparticles, resulting in reduced physical and colloidal stability,
which led to enhanced agglomeration.4. Final remarks and conclusions
In this study, we reported the use of MFI (a flow imaging micro-
scope) to characterize PLGAmicroparticles that serve as drug deliv-
ery systems for small molecules or peptides. The size distribution
of PLGA microparticles is commonly assessed with a static light
scattering or laser diffraction instrument such as Mastersizer. The
two techniques, Mastersizer and MFI, are based on different mea-
Table 4
Technical comparison between the Mastersizer 2000 and Micro-Flow Imaging 5100 instruments for the analysis of particle size distribution [15,16,25].
Mastersizer 2000 MFI 5100
Specifications
Measurement principle Laser diffraction according to Fraunhofer or Mie theory Digital microscopy of sample passing through a flow cell
Sizing range 0.02–2000 lm 2–300 lm
Sample type Suspension, also dry option Suspension





Light source HeNe laser 633 nm (red), LED 466 nm (blue) LED light
Detection Detector array for forward, side and back scattering High frequency acquisition of microscopic images
Solvent compatibility Wide range of solvents Aqueous sample fluids; limited compatibility with organic
solvents
Instrument operation
Level of training Basic Basic for acquisition; moderate to high for data processing
Measurement time One to several minutes per sample, optional autosampler Several minutes per sample, optional autosampler
Sample consumption High; e.g., 50–150 mg of PLGA microparticles in suspension Low; e.g., 0.5–1 mg of PLGA microparticles in suspension
Principle output Volume-based, equivalent spherical diameter Number-based, equivalent circular diameter
Sample visualization No Yes




Morphology No Yes; aspect ratio, circularity, maximum Feret diameter,
transparency of particles
Agglomeration No; only size shift Yes; quantitative assessment
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size analysis (Table 4).
We showed that Mastersizer and MFI measured similar
volume-based size distributions for the total particle population
of two commercial PLGA microparticle products (Fig. 2B and D).
We also demonstrated two key advantages of MFI over Master-
sizer: (1) MFI provides an actual number-based size distribution
due to the detection of individual particles (=quantitative method),
and (2) MFI enables the classification of PLGA microparticles into
distinct particle populations (i.e., fines, monospheres and agglom-
erates) based on morphological characteristics.
The size, quantity and morphology of particles in these sub-
populations are important quality attributes of a PLGA microparti-
cle product. For instance, if the size of the monospheres decreases,
this will increase the surface-area-to-volume ratio and thus
increase the rate of drug diffusing out of the particles [42]. Also,
water will more easily enter smaller particles owing to their larger
surface area, resulting in an enhanced ‘‘burst release” effect and
more rapid hydrolytic degradation of PLGA polymers. On the other
hand, an increase in PLGAmicroparticle size results in a decrease in
particle surface area, which will lead to a decrease in drug release
rate [43].
One particularly interesting application of MFI in the analysis of
PLGA microparticles is that it can determine whether a shift to lar-
ger sizes in a product is due to particles growing in size or particle
agglomeration. In case of particle growth, one would expect to see
a reduction in drug release rate. By contrast, agglomeration of par-
ticles would result in accelerated drug release due to the retention
of acidic PLGA degradation products inside the agglomerates,
which auto-catalyze hydrolysis of the polymers [26,44]. Moreover,
the surface area of an agglomerate consisting of multiple micropar-
ticles that are fused together is substantially larger than that of one
large microparticle with the same diameter as the agglomerate.
Lastly, agglomeration not only affects drug release rate but may
also compromise suspendability and injectability of a PLGA
microparticle product [43].
In conclusion, we have presented MFI as a valuable tool to
assess the size and agglomeration of PLGA microparticles, which
can serve to promote insight into the relationship between the for-mulation and process parameters, particle characteristics, physical
stability, drug release and (ultimately) the clinical efficacy of these
types of products.Acknowledgments
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